| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
BioAlliance Pharma (EPA: BIO)
BIO Technical Analysis
2
| As on 31st Jul 2014 BIO Share Price closed @ 7.40 and we RECOMMEND Buy for LONG-TERM with Stoploss of 6.51 & Strong Sell for SHORT-TERM with Stoploss of 7.91 we also expect STOCK to react on Following IMPORTANT LEVELS. |
BIO Share Price
| Open | 7.62 | Change | Price | % |
| High | 7.63 | 1 Day | -0.20 | -2.63 |
| Low | 7.36 | 1 Week | 0.00 | 0.00 |
| Close | 7.40 | 1 Month | 0.00 | 0.00 |
| Volume | 135061 | 1 Year | 0.00 | 0.00 |
| 52 Week High 208.85 | 52 Week Low 66.52 | ||||
EPA France Most Active Stocks
| MT | 4.53 | 12.97% |
| MT | 4.53 | 12.97% |
| GSZ | 17.56 | 3.97% |
| BRS | 12.00 | 0.00% |
| VK | 4.72 | 0.43% |
| ALALO | 0.04 | 0.00% |
| CS | 26.31 | 1.47% |
| TEC | 67.40 | 0.40% |
| ACA | 14.98 | 0.00% |
| ALAUP | 0.20 | -13.04% |
EPA France Top Gainers Stocks
EPA France Top Losers Stocks
| BIO Daily Charts |
BIO Intraday Charts |
Whats New @ Bazaartrend |
BIO Free Analysis |
|
|
BIO Important Levels Intraday
| SUPPORT | 0.00 |
| SUPPORT | 0.00 |
| RESISTANCE | 7.65 |
| RESISTANCE | 7.55 |
| SUPPORT | 7.25 |
| SUPPORT | 7.15 |
| SUPPORT | 0.00 |
| SUPPORT | 0.00 |
BIO Target for Month February
| 4th UP TARGET | 0 |
| 3rd UP TARGET | 0 |
| 2nd UP TARGET | 0 |
| 1st UP TARGET | 0 |
| 1st DOWN TARGET | 0 |
| 2nd DOWN TARGET | 0 |
| 3rd DOWN TARGET | 0 |
| 4th DOWN TARGET | 0 |
BIO Weekly Target
| 4th UP TARGET | 0.00 |
| 3rd UP TARGET | 0.00 |
| 2nd UP TARGET | 0.00 |
| 1st UP TARGET | 0.00 |
| 1st DOWN TARGET | 0.00 |
| 2nd DOWN TARGET | 0.00 |
| 3rd DOWN TARGET | 0.00 |
| 4th DOWN TARGET | 0.00 |
BIO Target for Year 2021
| 4th UP TARGET | 0 |
| 3rd UP TARGET | 0 |
| 2nd UP TARGET | 0 |
| 1st UP TARGET | 0 |
| 1st DOWN TARGET | 0 |
| 2nd DOWN TARGET | 0 |
| 3rd DOWN TARGET | 0 |
| 4th DOWN TARGET | 0 |
BioAlliance Pharma ( EPA France Symbol : BIO )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
BIO Business Profile
BioAlliance Pharma SA designs, develops, and markets drugs for the treatment of cancer primarily in France. Its specialty product portfolio includes Loramyc/Oravig, a mucoadhesive buccal tablet for the treatment of oropharyngeal candidiasis in patients with head and neck cancer or AIDS; Sitavig, a mucoadhesive buccal tablet to treat recurrent herpes labialis in immunocompetent patients; and Fluriad, an H1N1 vaccine that is in preclinical trials. The companyÂ’s ophan oncology product portfolio comprises Livatag, which is in phase III clinical trial for the treatment of hepatocellular carcinoma; Validive, a mucoadhesive buccal tablet that is in Phase II clinical trial for the prevention of chemo/radiation therapy-induced oral mucositis in patients with head and neck cancer; and AMEP/Synfoldin, a preclinical trial product for metastatic melanoma. BioAlliance Pharma SA was founded in 1997 and is based in Paris, France.
© 2005-2019 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
